Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05890872 · ClinicalTrials.gov registry record · NA
Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer
A NA study, sponsored by Galvanize Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT05890872 is a NA study that has completed, run by Galvanize Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT05890872, a NA study, has completed, sponsored by Galvanize Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to evaluate safety of delivering Aliya PEF in patients with metastatic cancer within the lungs or stage IV non-small cell lung cancer (NSCLC) who are treatment-naïve and indicated for first-line standard of care (SOC) cancer therapy.
Interventions
- DEVICE Aliya Pulsed Electric Fields (PEF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-09-06 |
| Est. Completion | 2025-08-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05890872
The ClinicalTrials.gov registry entry for NCT05890872 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galvanize Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aliya Pulsed Electric Fields (PEF) is the first listed.
NCT05890872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05890872 about?
NCT05890872 is a clinical study titled "Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer". The goal of this clinical trial is to evaluate safety of delivering Aliya PEF in patients with metastatic cancer within the lungs or stage IV non-small cell lung cancer (NSCLC) who are treatment-naïve and indicated for first-line standard of care (SOC) cancer therapy.
What is the current status of trial NCT05890872?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2023-09-06. Estimated completion is 2025-08-13.
What interventions are being tested in trial NCT05890872?
The interventions under investigation include: Aliya Pulsed Electric Fields (PEF) (DEVICE).
Who is sponsoring clinical trial NCT05890872?
This trial is sponsored by Galvanize Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.